Showing results (971-980 of 1,023) with videos related to

Sort By:
Pageof 103
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)P Jain, E Aoki, M Keating, et al.
PLOS Global Public Health|November 15, 2023
Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trialAhmed M Arzika, Ramatou Maliki, Abdou Amza, et al.
Journal of Thrombosis and Haemostasis : JTH|July 7, 2018
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndromeK Legault, H Schunemann, C Hillis, et al.
Plos One|February 9, 2026
Exploring heterogeneity in treatment effects: The impact and interaction of asset-based wealth and mass azithromycin distribution on child mortalityElisabeth A Gebreegziabher, Ali Sié, Mamadou Ouattara, et al.
ESMO Open|August 10, 2023
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerG Viale, M Basik, N Niikura, et al.
Leukemia|August 17, 2011
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibD Marin, I H Gabriel, S Ahmad, et al.
The Journal of Antimicrobial Chemotherapy|November 17, 2015
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistanceT Kostyanev, M J M Bonten, S O'Brien, et al.
The New England Journal of Medicine|June 6, 2019
Longer-Term Assessment of Azithromycin for Reducing Childhood Mortality in AfricaJeremy D Keenan, Ahmed M Arzika, Ramatou Maliki, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2025
Exploring Heterogeneity in Treatment Effects: The Impact and Interaction of Asset-Based Wealth and Mass Azithromycin Distribution on Child MortalityElisabeth A Gebreegziabher, Ali Sié, Mamadou Ouattara, et al.
Trials|February 19, 2026
Azithromycin mass drug administration to reduce child mortality in Niger (AVENIR II): a master protocol for a cluster-randomized adaptive platform trial to evaluate community-based health interventionsAhmed M Arzika, Abdou Amza, Sani Ousmane, et al.
Pageof 103